Increased expression of ARL1 and ARL11 in CM is associated with a favorable prognosis, while low expression of ARL15 is indicative of the poorest outcomes according to the clinical data available on the TCGA database. This evidence concerns the gene ARL15 and cutaneous mastocytosis.